The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

The FDA is phasing out an animal testing requirement for monoclonal antibody therapies in favor of testing drugs on ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other institutions, have successfully ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...